The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.
 
Paul Eliezer Oberstein
Consulting or Advisory Role - Amal Therapeutics; Aravive; AstraZeneca; AstraZeneca; Merck; QED Therapeutics; Rubius Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Amal Therapeutics (Inst); Arcus Biosciences (Inst); Merck (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst); Zai Lab (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); E-therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Menarini (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS
 
Kanwal Pratap Singh Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Yong Sang Hong
No Relationships to Disclose
 
Sae-Won Han
Honoraria - IMBdx
Research Funding - Arcus Biosciences (Inst); BeyondBio (Inst); GC Pharma (Inst); Genentech (Inst); Hanmi (Inst); Hengrui Pharmaceutical (Inst); IMBdx (Inst); Janssen (Inst); Jeil Pharmaceutical Co (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); MSD (Inst); Roche (Inst); Seagen (Inst); Turnstone Bio (Inst)
 
Yu-Li Su
Consulting or Advisory Role - Astellas Pharma
Speakers' Bureau - Bayer; Johnson & Johnson; Merck; MSD; Ono Pharmaceutical
 
Ying Yuan
No Relationships to Disclose
 
Filippo Pietrantonio
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Merck Serono; MSD Oncology; Pierre Fabre; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Janssen; Merck Serono; MSD Oncology; SERVIER; Takeda
Research Funding - Agenus (Inst); Amgen (Inst); Astrazeneca (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Merck Serono; Pierre Fabre
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; ALX Oncology; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Ipsen; Lilly; Merck KGaA; Merck Sharp & Dohme; Mirati Therapeutics; Nordic Group; Novartis; Pfizer; Pierre Fabre; Roche; Seagen; SERVIER; Taiho Pharmaceutical; Takeda; TERUMO; Zymeworks
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Amgen (I); California Institute for Regenerative Medicine (CIRM) (I); Elevar Therapeutics (Inst); Elevation Oncology; GlaxoSmithKline; Gritstone Bio (Inst); Hookipa Biotech; IgM Biosciences (I); Janssen Oncology; Merck (Inst); Merck Serono; natera; Pfizer; Pfizer (Inst); Seagen; Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst)
 
Joshua C Curtin
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Sanjib Chowdhury
Employment - Janssen Research & Development
 
Rianka Bhattacharya
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Raymond Scott Maul
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Ryota Iwasawa
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Robert W. Schnepp
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Roland Elmar Knoblauch
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Meena Thayu
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Gwo Fuang Ho
Honoraria - AstraZeneca; Boehringer Ingelheim; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); F. Hoffmann LaRoche (Inst); Janssen Research & Development (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regenacy Pharmaceuticals (Inst); Tessa Therapeutics (Inst)
Travel, Accommodations, Expenses - Dr. Reddy's; Regeneron
 
Han Sang Kim
No Relationships to Disclose